Gut Microbiota-dependent Health Impacts of Haskap Berries

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age35-65
SponsorMontana State University

About this trial

Polyphenol-rich Haskap berries (Haskap) have untapped therapeutic potential to improve human health, and agricultural producers in northern U.S. states are poised to increase production if consumer demand increases. A critical knowledge gap is that little is known about the interactions between gut microbes and Haskap polyphenols to produce bioactive metabolites linked to downstream health impacts. Additionally, little is known about which Haskap varieties and harvest timing yield the greatest bioactive potential. This study aims to address these gaps by investigating the interaction of bioactive components in Haskap with gut microbiota and the resultant gut and serum metabolites, inflammation, and metabolic health, and then couple this with analysis of berries from different Haskap varieties and harvest times.

Eligibility criteria

Qualifiers

Waist circumference: men ≤ 40, women ≤ 35 inches

Systolic blood pressure: ≤ 130 mmHg

Diastolic blood pressure: ≤ 85 mmHg

Fasting glucose: ≤ 100 mg·dl-1

Disqualifiers

BMI <18 or > 40 kg/m²

potential allergy to Haskap or placebo ingredients

use of anti-inflammatory, lipid lowering, glucose lowering, blood pressure, or any other medications that may interfere with study measures

pregnant or lactating woman

Trial design

Treatments tested in this trial

  • Haskap berry smoothie
  • Placebo comparator

Treatment groups

120 Participants
are divided into 4 treatment groups

Sponsors and collaborators

Montana State University

Lead sponsor

Montana State Agricultural Experiment Station

Collaborator